Clinitech Laboratory Limited will hold a meeting of its Board of Directors on August 17, 2026, to approve the company’s board report for FY26 and finalize arrangements for its 16th Annual General Meeting (AGM). The session, scheduled to begin at 11:30 AM IST via video conferencing, aims to conclude key governance procedures required before the upcoming shareholder vote.

The primary objective of the gathering is to review and adopt the Board’s report along with all associated annexures for the financial year 2025-26. This approval is a prerequisite for issuing the notice for the 16th AGM, which will include the determination of the date, time, and venue for the shareholder assembly. The Board will also finalize the book closure dates necessary for determining eligible shareholders.

In addition to financial approvals, the Board will address succession planning by considering the appointment of a director retiring by rotation. This standard governance procedure ensures continuity in leadership while adhering to statutory requirements for director tenure.

To ensure transparency in the upcoming voting process, the Board plans to finalize the appointment of Mr. Deep Shukla, a Practising Company Secretary, as the scrutinizer. His role will be to oversee the voting mechanism during the AGM, ensuring fairness and compliance with regulatory standards.

The intimation regarding this meeting was issued on August 12, 2026, pursuant to Regulation 29 and Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Jagdish Umakant Nayak, Chairman and Managing Director, signed the communication.

Key Agenda Items

Governance Compliance

The proceedings align with mandatory disclosure norms under the SEBI LODR framework. By scheduling the meeting through video conferencing, the company adheres to contemporary corporate governance practices that allow for flexible yet secure decision-making processes. The appointment of an independent scrutinizer further reinforces the integrity of the forthcoming AGM voting process.

Clinitech Laboratory reported a 7% increase in net profit to ₹42.25 lakh for the financial year ended March 31, 2026, compared to ₹39.47 lakh in the previous year. Revenue from operations grew 15% to ₹947.50 lakh from ₹823.49 lakh in FY25. The Board of Directors approved the audited standalone and consolidated financial results at a meeting held on May 28, 2026.

Financial Performance

The company’s total income for FY26 stood at ₹966.31 lakh, up from ₹846.26 lakh in the previous year. Total expenses increased to ₹905.93 lakh from ₹790.79 lakh. The basic earnings per share (EPS) for the year was ₹1.85, slightly lower than ₹1.90 in the prior year. For the half-year ended March 31, 2026, the company reported a profit after tax of ₹12.23 lakh.

Consolidated Results

On a consolidated basis, net profit for the year attributable to the owners of the parent company rose to ₹41.79 lakh from ₹39.47 lakh in FY25. Total consolidated revenue from operations reached ₹949.12 lakh, compared to ₹823.49 lakh in the previous year. Consolidated total income for the year was ₹967.93 lakh.

Capital Allocation and Cash Flows

The company’s cash and cash equivalents decreased to ₹206.46 lakh as of March 31, 2026, from ₹307.48 lakh a year earlier. Net cash generated from operating activities was negative at ₹89.55 lakh, while investing activities resulted in a net outflow of ₹43.99 lakh. The company raised ₹35.76 lakh from long-term borrowings during the year.

Regulatory Compliance

The statutory auditors, M/s Kale Malde & Co., issued an audit report with an "unmodified opinion" on the standalone and consolidated financial statements. The company also submitted a certificate regarding the utilization of IPO proceeds, confirming that ₹528.30 lakh had been utilized out of the total ₹578.30 lakh raised. The intimation regarding the board meeting was submitted to BSE Limited pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015.